LONDON (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) said Thursday that results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2-expressing advanced solid tumors, two secondary endpoints of the trial.
In the primary analysis, Enhertu continued to show durable responses based on investigator-assessed confirmed objective response rate (ORR), the primary endpoint of the trial, and duration of response (DoR), a secondary endpoint; reinforcing results from an interim analysis of the trial.
Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
For More Such Health News, visit rttnews.com
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX